Tolerability profile TKIs combotherapy was acceptable.<h4>Conclusion</h4>These case reports underline the therapeutic complexity of <i>EGFR</i>-acquired resistance mutation in <i>ALK<sup>+</sup></i> NSCLC and offers some leads to solve this real-life clinical challenge. Here, ALK is linked to non-small cell lung carcinoma.